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OBJECTIVE — To assess the ability to identify potential association(s) of diabetes medica-
tions with myocardial infarction using usual care clinical data obtained from the electronic
medical record.
RESEARCHDESIGNANDMETHODS — Wedeﬁnedaretrospectivecohortofpatients
(n  34,253) treated with a sulfonylurea, metformin, rosiglitazone, or pioglitazone in a single
academichealthcarenetwork.Allpatientswereaged18yearswithatleastoneprescriptionfor
oneofthemedicationsbetween1January2000and31December2006.Thestudyoutcomewas
acute myocardial infarction requiring hospitalization. We used a cumulative temporal approach
toascertainthecalendardateforearliestidentiﬁableriskassociatedwithrosiglitazonecompared
with that for other therapies.
RESULTS — Sulfonylurea, metformin, rosiglitazone, or pioglitazone therapy was prescribed
for11,200,12,490,1,879,and806patients,respectively.Atotalof1,343myocardialinfarctions
wereidentiﬁed.Afteradjustmentforpotentialmyocardialinfarctionriskfactors,therelativerisk
for myocardial infarction with rosiglitazone was 1.3 (95% CI 1.1–1.6) compared with sulfonyl-
urea, 2.2 (1.6–3.1) compared with metformin, and 2.2 (1.5–3.4) compared with pioglitazone.
Prospective surveillance using these data would have identiﬁed increased risk for myocardial
infarction with rosiglitazone compared with metformin within 18 months of its introduction
with a risk ratio of 2.1 (95% CI 1.2–3.8).
CONCLUSIONS — Our results are consistent with a relative adverse cardiovascular risk
proﬁle for rosiglitazone. Our use of usual care electronic data sources from a large hospital
networkrepresentsaninnovativeapproachtorapidsafetysignaldetectionthatmayenablemore
effective postmarketing drug surveillance.
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A
dverse events that occur infre-
quently during premarketing ran-
domizedclinicaltrialsorareunder-
reported with traditional postmarketing
methods of drug surveillance underscore
the need for additional methodologies
and data sources to monitor drug safety
(1). Critical insights may be realized by
monitoring large clinical databases using
automateddatafeedsinnearrealtime(2).
Diabetes medications present an ideal
paradigm to test new safety signal detec-
tion approaches because they are used
frequently in large numbers of patients
with type 2 diabetes, and new products
have been recently launched while suit-
able drug comparators remain marketed.
Existing concerns regarding adverse car-
diovascular risk for diabetes therapies
provide motivation for hypothesis-driven
prospective surveillance. Adverse cardio-
vascular side effects have been seen with
rosiglitazone (3,4). Although a recent
noninferiority clinical trial has provided
some evidence exonerating rosiglitazone
from a risk for excess mortality (5), con-
cern remains regarding a possible adverse
risk for myocardial infarction.
We tested an automated strategy an-
alyzing clinical data in real time to detect
adverse drug-related events. Because pre-
marketing clinical trials of diabetes thera-
pies are currently designed primarily to
evaluate efﬁcacy for glycemic improve-
ment and have not previously been de-
signed to assess relatively infrequent but
clinically important adverse outcomes,
active surveillance may play a valuable
role in assessment of risk (6). Active sur-
veillance could provide evidence of risk
earlier than postmarketing outcome tri-
als. Furthermore, it may be cost prohibi-
tive to conduct randomized controlled
trials for each drug product toward im-
portant hard safety outcomes. Although
such an analysis would not provide con-
clusive causal evidence, we determined
whether prospective analysis of clinical
data could have provided early evidence
ofcardiovascularriskassociatedwithros-
iglitazone that would warrant additional
evaluation.
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METHODS— We identiﬁed a cohort
of patients who had new prescriptions for
diabetes medications within Partners
Healthcare System, a large, nonproﬁt ac-
ademic health care network including
Brigham and Women’s and Massachu-
setts General Hospitals. The source of
clinicaldatawastheResearchPatientData
Registry, a centralized data warehouse in-
cluding patient demographic informa-
tion, dates of service, medications,
diagnoses, laboratory results, and dis-
charge summaries.
The retrospective cohort analysis in-
cluded all patients aged 18 years iden-
tiﬁed by an ICD-9 code for Diabetes
Mellitus (250.XX) or an A1C of 6.0%
and at least one record of prescription of
an oral diabetes medication as an outpa-
tient or dispensation as an inpatient, be-
tween 1 January 2000 and 31 December
2006.Analysesfocusedonthreeclassesof
diabetic medications: sulfonylureas, the
biguanide metformin, and the thiazo-
lidinediones, rosiglitazone and pioglita-
zone. Evidence of insulin therapy did not
exclude patients but was adjusted for in
multivariate models and used for strati-
ﬁed analysis (described below). We ex-
cluded patients receiving either metformin
or thiazolidinedione who had a diagnosis
of polycystic ovaries but not diabetes. For
each patient, all available associated data
were extracted, including narrative notes
andhospitaldischargesummaries.Narra-
tive notes were used for validating coded
medicationsanddiagnosesfoundinmed-
ical records, permitting determination of
sensitivity and speciﬁcity of events as re-
corded in the electronic medical record.
Patient enrollment, observation,
drug exposure, and event
identiﬁcation
The study population does not receive
health care exclusively within the Part-
ners system, and, thus, some patients
withinthesurveillancedatabasemayhave
had incomplete records. To address this
issue, we used health care encounters (in-
patient or outpatient) as a proxy for re-
ceipt of care at Partners over a speciﬁc
observation period. We constructed 14
6-month observation periods, beginning
on 1 January or 1 July between 2000 and
2006, during which a patient had at least
one outpatient ofﬁce visit, including psy-
chotherapy or nutrition visits, or an inpa-
tient encounter. Study entry was
consideredtheﬁrstperiodmeetingoneof
these criteria within the study dates.
For each patient, duration of expo-
sure to individual diabetes medications
was assessed in 6-month increments dur-
ing which only one of the four medica-
tions was prescribed. Patients receiving
multiple medications under consider-
ation were excluded. The study end point
for each evaluable patient was ﬁrst hospi-
talizationbetween1January2000and31
December 2006 for myocardial infarction
(ICD-9 code 410), death (all causes), a
gapincareinwhichtherewerenopatient
encountersinsubsequentobservationpe-
riods, or end of study in 2006. The ICD-9
diagnostic code for acute myocardial in-
farctionhasbeenvalidatedpreviously(7).
Events were associated with a particular
medication only when the prescription or
dispensation occurred within the 6
months before the documented myocar-
dial infarction. If a patient did not have
anyactivityfora6-monthobservationpe-
riod but resumed activity in the following
period, than the particular 6-month ob-
servation period with no activity was ex-
cluded from analysis. Analysis was
repeatedconsideringonlypatientshaving
been prescribed one of the four medica-
tions, considered to be monotherapy. Fi-
nally, we also performed stratiﬁcation of
our data to analyze patients who had not
received insulin as outpatient therapy.
We conducted a manual review of
outpatient notes and inpatient discharge
summaries on a random sample of 200
patients to validate use of electronic med-
ical record data to identify both drug ex-
posure and myocardial infarction events.
Review included patients identiﬁed as ex-
posed to rosiglitazone and with myocar-
dial infarction (n  50) or exposed and
without an event (n  50) as well as the
comparator group of patients (receiving
one of the other three oral diabetes med-
ications but not exposed to rosiglitazone)
and with (n  50) or without myocardial
infarctionevent(n50).Institutionalre-
view board approval was obtained for
medical record review.
Statistical analysis
The relative risk of myocardial infarction
associatedwiththerapywascalculatedfor
rosiglitazone compared with metformin,
sulfonylureas,orpioglitazone.Bothcrude
and adjusted rate ratios with 95% CIs
were estimated using generalized linear
modeling, assuming a Poisson distribu-
tion for the response and set duration of
time taking a particular medication (as
6-month intervals) as the offset. To ac-
count for overdispersion in the count
data, extra-Poisson variability was mod-
eled and incorporated into estimates of
SEs. Parameter estimates were trans-
formed to rate ratios.
Adjustments were made for potential
risk factors including age, sex, cardiovas-
cular disease prior to enrollment (deﬁned
by billing codes for coronary artery dis-
ease, myocardial infarction, angina, con-
gestive heart failure, cerebrovascular
incident, percutaneous coronary inter-
vention, and coronary artery bypass graft
surgery), any use of hypertensive medica-
tions, lipid-lowering medications, and
outpatient insulin use during study pe-
riod.Themodelalsoincludedadjustment
for underlying morbidity using an age-
adjusted Charlson score. In an additional
model, we evaluated potentially impor-
tant factors for which we had less than
complete data. These included race/
ethnicity (with information available in
93% of patients), insurance coverage
(commercial, Medicare, Medicaid, or un-
insured) (83%), A1C (60%), and creati-
nine (71%) levels. Overall mean A1C and
creatinine levels (2.0 or 2.0 mg/dl)
during the study period were considered
indicators of diabetes severity. Differ-
ences in these characteristics between
medication groups were identiﬁed with
ANOVA and a Tukey post hoc test. Fi-
nally, because previous myocardial in-
farction imparts a greater risk for
recurrent cardiovascular events (8) and
because of the need to consider starting
new medications to minimize potential
prolonged effects of prior diabetes thera-
pies on cardiovascular events, we tested a
model in which all patients who had ever
had a recorded inpatient stay for myocar-
dial infarction or had been prescribed a
diabetesmedicationintheyearbeforeen-
try were excluded.
Signal detection analysis
To construct a general surveillance ap-
proach to identify adverse events from
clinical data, we repeated the above anal-
ysis using a cumulative temporal ap-
proach by the deﬁned 6-month intervals.
All available data from the ﬁrst time pe-
riod(1January2000–31May2000)were
analyzed, and data were iteratively added
with each subsequent 6-month period.
Cumulative data were analyzed until the
ﬁnal period. Data were treated as cumu-
lative with additional new patients and
patient-year exposure providing in-
creased power to the analyses. A signiﬁ-
cant risk ratio (where the lower bound of
the 95% CI was 1.0) was considered to
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formedusingSASstatisticalsoftware(ver-
sion 9.0; SAS Institute, Cary, NC).
Numbers of prescriptions of pioglitazone
wereinsufﬁcientforcomparisonwithros-
iglitazone until 1 January 2002.
RESULTS— We identiﬁed 34,252 di-
abetic patients treated with at least one of
the four diabetes medications between 1
January 2000 and 31 December 2006. Of
the total 159,586 evaluable 6-month in-
tervals, there were 40,695 periods of sul-
fonylurea therapy (17,157 patients),
48,713 periods of metformin therapy
(18,162 patients), 8,707 periods of ros-
iglitazone therapy (4,274 patients), and
3,591 periods of pioglitazone therapy
(1,800 patients). When only one of the
four diabetes medications was prescribed
ina6-monthperiod,weidentiﬁed20,233
periods for sulfonylureas (11,200 pa-
tients), 27,860 periods for metformin
(12,490 patients), 2,834 periods for ros-
iglitazone (1,879 patients), and 1,290 pe-
riods for pioglitazone (806 patients)
(Table 1). When only one of the four di-
abetesmedicationswasprescribedduring
the entire period, we identiﬁed 7,152 pa-
tientstakingsulfonylureas,8,798patients
taking metformin, 1,028 patients taking
rosiglitazone, and 418 patients taking
pioglitazone. Given the large number of
patientsinthedifferenttreatmentgroups,
there were statistically signiﬁcant, al-
though generally small, differences in
many baseline variables. These were ad-
justedforinanalysestocontrolforknown
baseline differences.
We identiﬁed 1,343 hospitalized
myocardial infarction events and an over-
all event rate of 16.8 per 1,000 patient-
years. There were 768 events associated
withsulfonylureas(38.0eventsper1,000
patient-years), 406 with metformin (14.6
events per 1,000 patient-years), 133 with
rosiglitazone (46.9 events per 1,000 pa-
tient-years), and 36 with pioglitazone
(27.9 events per 1,000 patient-years).
Manual review of 235 randomly selected
patient records revealed a high level of
conﬁrmation for drug exposure to indi-
vidual medications, with both sensitivity
and speciﬁcity of 94%. Identiﬁcation of
myocardial infarction events was con-
ﬁrmedwithasensitivityof93%andspec-
iﬁcity of 74%. Lower speciﬁcity was
primarily due to the presence of previous
and “rule out” myocardial infarctions
noted in patient records. Overall, there
werenodifferencesinspeciﬁcityandsen-
sitivity of myocardial infarction by drug
type.
Rosiglitazone was associated with an
unadjusted rate ratio for increased myo-
cardialinfarctionof1.2(95%CI1.0–1.3)
compared with sulfonylureas, 3.3 (2.9–
3.6) compared with metformin, and 1.7
(1.3–2.1) compared with pioglitazone.
Afteradjustmentforidentiﬁedriskfactors
(age, sex, cardiovascular disease, hyper-
tensive medications, lipid-lowering med-
ications, and age-adjusted Charlson
score), individuals treated with rosiglita-
zone had an increased rate ratio for myo-
cardial infarction risk of 1.3 (1.0–1.6)
compared with sulfonylurea, 2.7 (2.2–
3.4) compared with metformin, and 1.7
(1.1–2.6) compared with pioglitazone.
Additional adjustments for factors with
limited data in our patient population
(race/ethnicity, insurance coverage, A1C,
and creatinine levels) resulted in only
small differences in adjusted relative risk.
In the model with additional factors not
availablefortheentirepopulation,rosigli-
tazone was associated with a relative risk
of myocardial infarction compared with
sulfonylurea, metformin, and pioglita-
zone of 1.4 (95% CI 1.0–1.9), 2.4 (1.0–
Table 1—Characteristics of the population
Rosiglitazone Metformin Sulfonylurea Pioglitazone
n 1,879 12,490 11,200 806
Age* 64.0  11.4 61.7  12.2 65.8  12.1 63.7  11.5
Female sex 908 (48.3) 6,628 (53.1) 4,760 (42.5) 384 (47.6)
Myocardial infarction outcome 133 (7.1) 406 (3.3) 768 (6.9) 36 (4.5)
Prior myocardial infarction 234 (12.5) 1,421 (11.4) 1,945 (17.4) 94 (11.7)
Prior cardiovascular disease 597 (31.8) 3,369 (27.0) 4,544 (40.6) 251 (31.1)
Hypertension 1,689 (89.9) 10,454 (83.7) 10,076 (90.0) 709 (88.0)
Hyperlipidemia 1,466 (78.0) 8,484 (67.9) 7,545 (67.4) 602 (74.7)
Chronic renal insufﬁciency (creatinine 2 mg/dl) 338 (18.0) 936 (7.5) 2,374 (21.2) 121 (15.0)
Outpatient insulin use 446 (23.7) 2,341 (18.7) 1,425 (12.7) 263 (32.6)
A1C 8.0  1.7 7.8  1.7 7.7  1.7 8.1  1.8
Antihyperlipidemic medication use 1,340 (71.3) 7,721 (61.8) 6,610 (59.0) 556 (69.0)
Combination 35 (1.9) 90 (0.7) 80 (0.7) 19 (2.4)
Fibrates 191 (10.2) 887 (7.1) 730 (6.5) 86 (10.7)
Statins 1,287 (68.5) 7,473 (59.8) 6,428 (57.4) 526 (65.3)
Antihypertensive medication use 1,535 (81.7) 9,358 (74.9) 8,620 (77.0) 649 (80.5)
ACE inhibitors 1,096 (58.3) 7,019 (56.2) 6,108 (54.5) 463 (57.4)
Angiotensin II antagonists 406 (21.6) 1,931 (15.5) 1,697 (15.2) 170 (21.1)
-Blockers 1,033 (55.0) 5,490 (44.0) 6,138 (54.8) 400 (49.6)
Calcium channel blockers 551 (29.3) 2,783 (22.3) 3,219 (28.7) 204 (25.3)
Combinations 275 (14.6) 1,844 (14.8) 1,315 (11.7) 123 (15.3)
- 163 (8.7) 739 (5.9) 1,068 (9.5) 47 (5.8)
Potassium-sparing diuretics 5 (0.3) 67 (0.5) 73 (0.7) 4 (0.5)
Unclassiﬁed combinations 10 (0.5) 24 (0.2) 17 (0.2) 4 (0.5)
Age-adjusted Charlson score* 7.9  4.4 7.1  4.2 8.5  4.5 7.5  4.2
Data are n (%) or means  SD. *Age at index date.
Myocardial infarction and diabetes medications
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Analyses restricted to patients without
prior myocardial infarction (29,055 of
34,252) and patients with no prior diabe-
tes medication in the 12 months before
enrollment (30,142 of 34,252) had no ef-
fect on model results.
Considering only patients receiving
monotherapy, rosiglitazone was associ-
ated with an unadjusted rate ratio for in-
creasedmyocardialinfarctionof1.1(95%
CI 1.0–1.3) compared with sulfonyl-
ureas, 3.5 (3.1–3.9) compared with met-
formin,and1.9(1.4–2.5)comparedwith
pioglitazone. After adjustment for identi-
ﬁed risk factors, individuals treated with
rosiglitazone had an increased rate ratio
for myocardial infarction of 1.2 (1.0–1.4)
compared with sulfonylurea, 2.5 (2.0–
3.2) compared with metformin, and 1.7
(1.3–2.2) compared with pioglitazone. In
the model with additional factors not
availablefortheentirepopulation,rosigli-
tazone was associated with a relative risk
of myocardial infarction compared with
sulfonylurea, metformin, and pioglita-
zone of 1.3 (95% CI 1.1–1.6), 2.2 (1.6–
3.1), and 2.2 (1.5–3.4), respectively.
After performing stratiﬁcation of our
data to analyze patients who had not re-
ceived insulin as an outpatient therapy,
we found that rosiglitazone was associ-
ated with an unadjusted rate ratio for in-
creasedmyocardialinfarctionof1.3(95%
CI 1.1–1.4) compared with sulfonylurea
and 3.5 (3.2–3.9) compared with met-
formin. After adjustment for identiﬁed
risk factors, individuals treated with ros-
iglitazone had an increased rate ratio for
myocardial infarction risk of 1.3 (1.0–
1.7)comparedwithsulfonylureasand3.0
(2.4–3.7) compared with metformin. In
the model with additional factors not
availablefortheentirepopulation,rosigli-
tazone was associated with a relative risk
of myocardial infarction compared with
sulfonylureas and metformin of 1.4 (95%
CI 1.0–2.0) and 2.6 (1.8–3.6), respec-
tively. No myocardial infarctions were
identiﬁed among the 594 patients receiv-
ing pioglitazone without additional insu-
lin outpatient therapy.
The iterative temporal analysis to de-
ﬁne the earliest possible date a safety sig-
nal would have been detected (Fig. 1)
demonstrates that a safety signal would
have been identiﬁed for rosiglitazone
compared with metformin after 18
monthsinJuly2001withanadjustedrisk
ratio of 2.1 (95% CI 1.2–3.8). Compared
with sulfonylurea or pioglitazone, rosigli-
tazone safety signals would have been
identiﬁed by January 2005 with adjusted
risk ratios of 1.2 (1.1–1.8) and 1.8 (1.0–
3.4), respectively.
CONCLUSIONS— A recent meta-
analysis of available case-control and
cohort studies derived from the rosiglita-
zone phase III clinical dataset suggested a
43% increased risk for cardiovascular
events in patients receiving rosiglitazone
(3). Many factors contribute to uncer-
tainty regarding these ﬁndings, including
availability of only summary trial-level
data rather than patient-level data, heter-
ogeneity of trial design, and absence of
uniformeventadjudication(9).However,
review of patient-level data by the U.S.
Food and Drug Administration (FDA)
yielded similar relative risk ﬁndings (10).
Absolute risk was low because cardiovas-
cular event rates were sparse in these
studies and statistical methods to deal
with infrequent event rates yield uncer-
tainty regarding validity of the risk (11).
Likewise, phase IV studies in patients
with type 2 diabetes have neither con-
ﬁrmed nor excluded an increased hazard
ratio for rosiglitazone (12,13), and, simi-
larly, large randomized multicenter trials
in high-risk diabetic patients with sub-
stantial use of rosiglitazone neither con-
ﬁrm nor exclude increased risk (14,15).
The recently completed phase IV Rosigli-
tazone Evaluated for Cardiovascular Out-
comes Regulation of Glycaemia in
Diabetes (RECORD) study was designed
as a noninferiority study comparing ros-
iglitazone plus either sulfonylurea or
metformin versus metformin and sulfo-
nylurea. Although it was underpowered
and treatment crossover complicated in-
terpretation of ﬁndings, relative risk for
mortality was 1.0; however, risk for
myocardial infarction with rosiglitazone
was 1.14, leaving the risk of rosiglitazone
formyocardialinfarctionuncertain(5).In
contrast, results of randomized phase IV
clinicaltrialsandmeta-analyseshavesug-
gested pioglitazone to be neutral to favor-
ableincardiovascularriskproﬁle(16,17).
The thiazolidinediones rosiglitazone
andpioglitazonebothgainedFDAapproval
within a short time span, have similar indi-
cations for being prescribed, have similar
cost, and are initially without apparent pre-
scription bias. A comparison of these two
products reduces the likelihood of comor-
bidities and unmeasured variables con-
founding ﬁndings, which might cause
greater potential bias for drugs of different
class, cost, or safety proﬁles. Thus, evaluat-
ing cardiovascular safety of approved oral
diabetes therapies in a real-world setting
providescontext,internalmodelvalidation,
and potentially valuable clinical informa-
tion for health care providers.
Our results are consistent with a pre-
viously suggested protective effect for
Figure 1—Temporal analysis to ascertain the calendar date for earliest identiﬁable risk associ-
ated with rosiglitazone compared with other therapies is shown with each curve representing
relative risk ratio of myocardial infarction for patients on rosiglitazone compared with alterna-
tively prescribed medications (sulfonylurea, metformin, and pioglitazone).
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pioglitazone (16,17), and potential rela-
tive adverse cardiovascular safety proﬁle
for rosiglitazone (19,3,4,20). In particu-
lar, our results comparing rosiglitazone
with pioglitazone complement other re-
cent ﬁndings (19,20) and are not likely to
be confounded by indication, given the
similar prescribing patterns. Together,
these ﬁndings demonstrate that methods
for medical record surveillance may pro-
vide useful adjunct methods to assess
postmarketing drug safety.
It is interesting that the relative risk
conﬁdence limits boundary either
touches or is near 1.0 in all analysis for
rosiglitazone compared with sulfonyl-
ureas. Sulfonylureas are established
agents that have been used for the treat-
ment of type 2 diabetes since approval in
the 1950s. Our ﬁndings are consistent
withthoseinthemeta-analysisperformed
by the FDA (10), which suggested no in-
crease in risk for rosiglitazone compared
with this established therapeutic class.
Our results do differ somewhat from
otherrecentstudies.Ananalysisofpoten-
tially more robust data showed similar
trends of decreased relative risk for car-
diovascular disease with metformin and
increased relative risk for sulfonylureas,
but they did not show signiﬁcant in-
creased relative risk for rosiglitazone
compared with pioglitazone (21). How-
ever, this ﬁnding contrasts with other ob-
servationalstudiesshowingincreasedrisk
with rosiglitazone (19,22). Differences
among patient populations, in absolute
event rates, or in methodologies may un-
derlie differences in the magnitude of rel-
ative risks in such studies.
Importantly, combined treatments
for dyslipidemia, hypertension, anti-
thrombotic agents, and glycemia have
markedly reduced event rates in patients
with type 2 diabetes, and these gains are
realized using strategies that include ros-
iglitazone (13,14). Relative risk analysis
may be used to inform a provider regard-
ingpriorityforselectingamongtreatment
options, but individual patient comor-
bidities and tolerance must also be con-
sidered when one is choosing among
speciﬁc therapeutic options, and absolute
risk must be carefully considered before
withholding a therapeutic option.
Our analysis does have important
limitations.Wedonothavecompletelon-
gitudinal prescription data for all individ-
ual patients, and patients may not take
medication that has been prescribed.
Hence we cannot conﬁrm for all patients
whether they were taking a medication at
the time of myocardial infarction. Al-
though we have derived an estimate of
recentexposure,deﬁningtrueexposureis
currently not possible with usual clinical
data. We may also have missed patients
who did have exposure. Prescriptions for
diabetes medications may have been ob-
tained outside the Partners system and
may therefore not have been captured.
However, this situation would underesti-
mate rather than overestimate drug risk.
Our use of other diabetes medications as
comparators, however, should reduce or
eliminate the majority of these potential
biases, although we cannot fully exclude
biases introduced by physicians or pa-
tients leading to selection of speciﬁc
drugs. Furthermore, there may be in-
creased cardiovascular risk with rosiglita-
zone for patients using insulin, which
may also be a surrogate for duration of
diabetes. In addition to adjusting for in-
sulin in our models, we performed strati-
ﬁcation, yielding very similar results.
Notably, no patients receiving pioglita-
zone without additional outpatient insu-
lin were identiﬁed to have a myocardial
infarction. Future analyses should consider
drug combinations because concomitant
use of insulin and thiazolidinediones may
be particularly unfavorable (10,21). Fur-
thermore, our low speciﬁcity for detec-
tion of myocardial infarction events of
74% is of particular concern, indicating a
need for future analyses to incorporate
laboratorydatatoverifytheoccurrenceof
myocardial infarction more accurately.
Composite end points of major adverse
cardiovascular events are standard mea-
sures for comparing treatments in large
cardiovascular outcome studies. Our
analysis included only myocardial infarc-
tion,whereasothercardiovascularevents,
such as sudden death and stroke, were
not considered in this analysis. Finally, if
there is increased health risk shortly after
initiationoftherapythatisabrogatedwith
longer duration of administration, then
cumulative assessments including addi-
tional new patients and patient-year ex-
posure would tend to produce a bias
toward early risk.
The control of residual confounders
in observational data is an important is-
sue. Approaches addressing this issue in
medical record data include comparing
risk in groups for the measured outcome
before and after an exposure (23) to test
whether a group was at prior higher risk,
picking comparable exposures (medica-
tions in the same class) where heuristi-
cally there is no reasonable argument for
differences in groups, and using global,
acceptedmeasurementsofacuity(suchas
the Charlson score) to detect differences
in underlying health of groups. We se-
lected the latter method, since there was
somesuggestionofriskdifferencesforthe
twomarketedthiazolidinedioneproducts
available for study.
Although the increased risk ratio for
rosiglitazone compared with other diabe-
tesmedicationshasbeendemonstratedin
more robust clinical datasets with ade-
quate longitudinal records of patients
(21), the current study provides two
novel and important insights. First, with
the need to monitor numerous products
and numerous potential events, it is in-
creasingly difﬁcult to develop random-
ized clinical trials to adequately address
all potential study bias and confounding
factors.Fromasurveillanceperspective,a
real-time strategy detecting risk that may
requirefurtherinvestigationispotentially
more cost-effective than numerous long-
term investigations into one drug–one
event relationships. Moreover, designing
studies to identify relatively infrequent,
but medically important, adverse events
that would probably be missed by phase
III clinical trials and current postmarket-
ing voluntary reporting mechanisms
would probably be expensive and curtail
or delay development of new treatments.
Surveillance analysis should be guided by
a priori evidence (such as nonstatistically
signiﬁcant adverse events) from phase III
clinical trials to limit the potential for
false-positive results. It is important to
note that surveillance methods work best
when agents have adequate population
uptake. For instance, the time to identify
signals comparing rosiglitazone and pio-
glitazone was delayed because of low
sample sizes for both drugs. Methodolo-
gies that improve detection performance,
especiallywhendrugsandeventsarerare,
or permit all possible drug-event interac-
tions are described elsewhere (24).
Second, our study shows how rela-
tively simple clinical surveillance meth-
ods can be implemented in real time.
Withtheavailabilityofelectronicdatasets
such as the one used herein, it is possible
to perform analyses of drug-event combi-
nations prospectively on a quarterly,
monthly, or even weekly basis. In this
study, we demonstrated that if these
methods had been in use when thiazo-
lidinediones were ﬁrst introduced to the
market, a potential hazard would have
been apparent 18 months after the
Myocardial infarction and diabetes medications
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were raised publicly in 2007 (3). This
time frame is also faster than would be
realized in phase IV postmarketing trials
and may cause less delay than requiring
cardiovascular outcome trials before FDA
approval for diabetes medications that do
not have adverse safety signals in aggre-
gate phase II–III study analysis. Although
these methods would not provide the
same degree of information as a prospec-
tive randomized control trial, they might
indicate caution to care providers faced
with options to prescribe multiple newer
medications, fulﬁlling clear needs for com-
plementary approaches (25).
Our study provides a framework for
implementation of future postmarketing
surveillance activities with semiauto-
matedextractionoflargeclinicaldatasets.
Despite inherent limitations, these data
canproviderobustreal-timesignalsofad-
verse drug events in the postmarketing
setting. How such systems will interact
with activities at the FDA requires
thoughtful consideration.
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